evidencegaps
Primary study · included by 1 review

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.

Chen 2023 · Chen Xiaofeng, Xu Xiang, Wang Danping, et al. · Journal for immunotherapy of cancer · 2023

Included by

The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas.
Non-Cochrane · intervention · 2026 · cited as Chen 2023 · Supplementary Table S1; reference list

The review does not say which of its outcomes this study informs.

1 including review in total.